These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 18201425)
1. Pharmacotherapy of asthma: what do the 2007 NAEPP guidelines say? Schatz M Allergy Asthma Proc; 2007; 28(6):628-33. PubMed ID: 18201425 [TBL] [Abstract][Full Text] [Related]
2. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. National Asthma Education and Prevention Program J Allergy Clin Immunol; 2007 Nov; 120(5 Suppl):S94-138. PubMed ID: 17983880 [TBL] [Abstract][Full Text] [Related]
3. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Chipps BE; Figliomeni M; Spector S Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179 [TBL] [Abstract][Full Text] [Related]
4. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. Prenner BM Curr Opin Pulm Med; 2008 Jan; 14(1):57-63. PubMed ID: 18043276 [TBL] [Abstract][Full Text] [Related]
5. Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines. Kelly HW J Allergy Clin Immunol; 2007 Nov; 120(5):989-94; quiz 995-6. PubMed ID: 17983867 [TBL] [Abstract][Full Text] [Related]
6. Medical Therapy for Asthma: Updates from the NAEPP Guidelines. Elward KS; Pollart SM Am Fam Physician; 2010 Nov; 82(10):1242-51. PubMed ID: 21121536 [TBL] [Abstract][Full Text] [Related]
7. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715 [TBL] [Abstract][Full Text] [Related]
8. Inhaled corticosteroids in children with persistent asthma: effects on growth. Zhang L; Prietsch SO; Ducharme FM Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972 [TBL] [Abstract][Full Text] [Related]
9. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. Eltonsy S; Forget A; Beauchesne MF; Blais L J Allergy Clin Immunol; 2015 Jan; 135(1):123-30. PubMed ID: 25226849 [TBL] [Abstract][Full Text] [Related]
10. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE J Manag Care Pharm; 2006 May; 12(4):310-21. PubMed ID: 16792437 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960 [TBL] [Abstract][Full Text] [Related]
12. Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8. Koster ES; Wijga AH; Zuidgeest MG; Belitser SV; Raaijmakers JA; Koppelman GH; Postma DS; Brunekreef B; de Jongste JC; Maitland-van der Zee AH Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):991-9. PubMed ID: 20712022 [TBL] [Abstract][Full Text] [Related]
13. Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma. van Aalderen WM; Grigg J; Guilbert TW; Roche N; Israel E; Martin RJ; Colice G; Postma DS; Hillyer EV; Burden A; Thomas V; von Ziegenweidt J; Price D J Allergy Clin Immunol Pract; 2015; 3(5):721-31.e16. PubMed ID: 26032474 [TBL] [Abstract][Full Text] [Related]
14. Management of asthma in children. Kemp JP; Kemp JA Am Fam Physician; 2001 Apr; 63(7):1341-8, 1353-4. PubMed ID: 11310649 [TBL] [Abstract][Full Text] [Related]